EP Patent

EP4157227A1 — Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists

Assigned to Sumitomo Pharma Co Ltd · Expires 2023-04-05 · 3y expired

What this patent protects

The present disclosure includes combination solid oral dosage forms having 40 mg of N- (4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a …

USPTO Abstract

The present disclosure includes combination solid oral dosage forms having 40 mg of N- (4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and hormone replacement medicaments. Also provided are processes for making and using the solid oral dosage forms.

Drugs covered by this patent

Patent Metadata

Patent number
EP4157227A1
Jurisdiction
EP
Classification
—
Expires
2023-04-05
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.